Aardvark Therapeutics, Inc. (NASDAQ:AARD) Given Average Rating of “Hold” by Brokerages

Aardvark Therapeutics, Inc. (NASDAQ:AARD) has been given an average recommendation of “Hold” by the thirteen research firms that are presently covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating, four have issued a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $19.70.

A number of analysts have recently weighed in on AARD shares. BTIG Research cut Aardvark Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, May 15th. B. Riley Financial reduced their price objective on Aardvark Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a research report on Friday, May 15th. Morgan Stanley restated an “underweight” rating and set a $3.00 price objective (down from $7.00) on shares of Aardvark Therapeutics in a research note on Friday, May 15th. Finally, Weiss Ratings raised Aardvark Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, July 2nd.

Hedge Funds Weigh In On Aardvark Therapeutics

Several institutional investors have recently modified their holdings of AARD. UBS Group AG increased its holdings in shares of Aardvark Therapeutics by 5.4% in the 3rd quarter. UBS Group AG now owns 54,728 shares of the company’s stock worth $727,000 after acquiring an additional 2,804 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in Aardvark Therapeutics in the 2nd quarter valued at about $42,000. Bank of America Corp DE boosted its stake in Aardvark Therapeutics by 72.9% during the 2nd quarter. Bank of America Corp DE now owns 7,989 shares of the company’s stock valued at $108,000 after purchasing an additional 3,369 shares during the period. China Universal Asset Management Co. Ltd. acquired a new position in Aardvark Therapeutics during the 4th quarter valued at about $47,000. Finally, Persistent Asset Partners Ltd bought a new position in Aardvark Therapeutics in the 4th quarter worth about $56,000.

Aardvark Therapeutics Stock Down 5.3%

Shares of NASDAQ:AARD opened at $5.00 on Friday. The company has a market cap of $109.40 million, a PE ratio of -1.56 and a beta of 3.93. Aardvark Therapeutics has a fifty-two week low of $3.35 and a fifty-two week high of $17.94. The firm has a 50-day simple moving average of $4.71 and a 200 day simple moving average of $7.85.

Aardvark Therapeutics (NASDAQ:AARD) last issued its earnings results on Thursday, May 7th. The company reported ($0.99) earnings per share (EPS) for the quarter. As a group, research analysts forecast that Aardvark Therapeutics will post -3.46 EPS for the current fiscal year.

Aardvark Therapeutics Company Profile

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (RORγ). RORγ plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.

The company’s lead programs consist of selective RORγ inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders.